Treatment guided by leftover leukemia cells in adults with acute myeloid leukemia
Tests quizartinib and venetoclax added to chemotherapy in adults with newly diagnosed acute myeloid leukemia.
Key facts
- Who runs it
- Centre Hospitalier Universitaire De Toulouse
- Where
- Amiens Cedex 1, Angers, Argenteuil Cedex, Avignon Cedex 9, Bayonne, Besancon Cedex, Béziers, Bobigny Cedex, Brest, Caen, Chambéry, Clamart, Clermont-Ferrand, Corbeil Essonnes Cedex, Creteil Cedex, Dijon, Dunkirk Cedex 1, Epagny Metz-tessy, Grenoble Cedex 9, Le Chesnay Rocquencourt, Lens, Lille, Lille Cedex, Limoges Cedex 1, Lyon, Marseille, Meaux, Metz Cedex 03, Montpellier Cedex 5, Mulhouse, Nantes, Nice, Nimes Cedex 9, Orleans Cedex 2, Paris, Perpignan Cedex, Pessac, Pierre-Bénite, Poitiers, Pontoise, Reims Cedex, Rennes, Roubaix, Rouen Cedex, Saint-Priest-en-Jarez, Strasbourg Cedex 2, Toulouse, Tours, Vandoeuvre Les Nancy, and Villejuif, FranceSee the 52 sites
- Trial code
- Registry title
- Prospective evaluation of response to treatment by analysis of measurable residual disease in younger adult patients (18-60 years) with acute myeloid leukemia (AML). The Backbone InterGroup (BIG)-2 umbrella trial from the Acute Leukemia French Intergroup (ALFA, FILO) - BIG2
- Status
- Not yet recruiting
- Phase
- Phase 4
- People taking part
- 1,290 people, planned
- Started
- 1 Sept 2026
- Expected to end
- 31 Dec 2037
- Type of study
- Interventional
- Record updated
- 23 October 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 18 to 60 with newly diagnosed acute myeloid leukemia who have had no earlier treatment for it and can have intensive chemotherapy. It has three parts, depending on the FLT3-ITD mutation and the response after the first chemotherapy cycle.
- Age
- 18 to 60 years (at least 18 and under 61).
- Sex
- All sexes can join.
- Disease stage
- Newly diagnosed acute myeloid leukemia (new, or arising from known myelodysplastic syndrome, or after cancer treatment). Part 1: FLT3-ITD mutation, not CBF-AML. Part 2: no response, or remission with leukemia cells still found (MRD 0.1% or more) after one 7+3 cycle. Part 3: remission with no leukemia cells found (MRD under 0.1%) after one 7+3 cycle.
- Earlier treatment
- No earlier treatment for leukemia (hydroxyurea allowed) or for myelodysplastic syndrome (only growth factors allowed). Part 1: no earlier quizartinib or other FLT3 inhibitors. Part 2: no earlier venetoclax.
- Biomarker or test result
- Part 1: FLT3-ITD mutation in the bone marrow (allelic ratio 0.03 or more). Parts 2 and 3: no FLT3-ITD mutation, except people with CBF-AML.
Main reasons for not taking part
- Pregnant or breastfeeding women
- Acute promyelocytic leukemia, or BCR::ABL1 or Ph1+ disease
- Leukemia arising from a known myeloproliferative neoplasm
- Serious heart problems (part 1), or uncontrolled severe infection
- Another cancer not stable for at least 2 years (except in-situ and skin cancer)
The registry criteria, word for word
Show all 36 criteriaShow less
Who can take part
- Age ≥ 18 years and < 61 years
- Health insurance coverage
- Sub-study 1 : Presence of FLT3-ITD activating mutation in bone marrow (allelic ratio ≥ 0.03)
- Sub-study 1 : Receiving standard 7+3 induction chemotherapy regimen as specified in the protocol
- Sub-study 1: Serum electrolytes within the institution’s normal limits: potassium, calcium (total calcium, calcium corrected for serum albumin in case of hypoalbuminemia, or ionized calcium), and magnesium
- Sub-study 2: Refractory (no response) or CR/CRh/CRi with positive MRD by MFC in bone marrow (≥ 0.1%) after one cycle of 7+3 induction
- Sub-study 2: Eligible for a second cycle of intensive chemotherapy
- Sub-study 3: CR/CRh/CRi without MRD by MFC in bone marrow (< 0.1% OR < LOD) after one cycle of 7+3 induction
- Signed written informed consent
- Newly diagnosed de novo AML, or secondary AML arising from a previously known myelodysplastic syndrome (MDS), or post cytotoxic therapy-related AML (AML-pCT), according to the 2022 WHO classification
- No prior treatment for AML (with the exception of hydroxyurea) or for MDS (with the exception of hematopoietic growth factors)
- ECOG performance status ≤ 3
- Eligible to induction chemotherapy
- No contraindication to anthracyclines: decompensated or uncontrolled heart failure, recent myocardial infarction, current signs of cardiac impairment, uncontrolled arrhythmias, or left ventricular ejection fraction (LVEF) < 50%
- Total bilirubin ≤ 2 x upper limit of normal (UNL), ASAT (SGOT) and ALAT (SGPT) ≤ 2.5 X UNL, creatinine < 150 µmol/l, unless AML-related values
- Women of childbearing potential should use appropriate methods of contraception
Who cannot take part
- Patients with secondary AML arising from a previously known myeloproliferative neoplasm (MPN) according to the 2022 WHO classification
- Sub-study 1: Prior treatment with quizartinib or other FLT3 inhibitors
- Sub-study 1: Treatment with any strong or moderate CYP3A inducers within 2 weeks or 5 half-lives of randomization whichever is longer
- Sub-study 2: Prior venetoclax exposure
- Patients with t(9;22)(q34.1;q11.2)/BCR::ABL1 or previous Ph1+ disorder (chronic myelogenous leukemia)
- Sub-study 2: Uncontrolled infection such as sepsis, or multiple organ dysfunction syndrome, uncontrolled fever
- Sub-study 2: Documented uncontrolled fungal infection (positive blood test and cultures)
- Severe psychiatric or organic disorder, supposed to be independent from AML, that would contraindicate treatment, including allogeneic HSCT
- Prior cancer, if not stable for at least two years, except in-situ carcinoma and skin carcinoma
- Uncontrolled severe infection at study entry
- Patients with uncontroled HIV-1 and -2 infection, or active hepatitis virus B or C infection
- Sub-study 1: Uncontrolled or significant cardiovascular disease, including any of the following: • Bradycardia < 50 beats per minute • QTcF interval >450 msec • Diagnosis of or suspicion of long QT syndrome (including family history of long QT syndrome) • Systolic blood pressure ≥180 mm Hg or diastolic blood pressure ≥110 mm Hg • History of clinically relevant ventricular arrhythmias (e.g., ventricular tachycardia, ventricular fibrillation, or torsade de pointes) • History of second (Mobitz II) or third-degree heart block (patients with pacemakers were eligible if they had no history of fainting or clinically relevant arrhythmias while using the pacemaker) • History of uncontrolled angina pectoris or myocardial infarction within 6 months before screening • History of New York Heart Association class 3 or 4 heart failure • Left ventricular ejection fraction ≤45% or less than the institutional lower limit of normal per multigated acquisition scan or echocardiogram done within 30 days before randomization • Complete left bundle branch block
- Pregnant or lactating women
- Sub-study 1: Patients with CBF-AML
- Sub-study 1: Uncorrected Grade 3 or 4 hypokalemia, hypomagnesemia or hypocalcemia. Subjects with Grade 1 or 2 electrolyte abnormalities can be enrolled while electrolytes are being corrected
- Sub-study 2: Patients with AML with FLT3-ITD mutation without CBF
- Legal incapacity (patients under tutorship, curatorship or judicial protection)
- Sub-study 3: Patients with AML with FLT3-ITD mutation without CBF
- Patients with acute promyelocytic leukemia (APL), as confirmed either by t(15;17) or by the presence of PML::RARA fusion transcripts
- Any psychological, familial, social, or geographic reason that would compromise clinical follow up
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 64 years old?
Where in France
- Centre Hospitalier Universitaire Amiens PicardieAmiens Cedex 1, FranceNot yet recruiting
- Centre Hospitalier Universitaire D'AngersAngers, FranceNot yet recruiting
- Centre Hospitalier Victor DupouyArgenteuil Cedex, FranceNot yet recruiting
- Centre Hospitalier D AvignonAvignon Cedex 9, FranceNot yet recruiting
- Centre Hospitalier de la Cote BasqueBayonne, FranceNot yet recruiting
- Centre Hospitalier Regional UniversitaireBesancon Cedex, FranceNot yet recruiting
- Centre Hospitalier de BéziersBéziers, FranceNot yet recruiting
- Assistance Publique Hopitaux De ParisBobigny Cedex, FranceNot yet recruiting
- Centre Hospitalier Régional et Universitaire de BrestBrest, FranceNot yet recruiting
- Centre Hospitalier Universitaire de Caen NormandieCaen, FranceNot yet recruiting
- Centre Hospitalier Métropole SavoieChambéry, FranceNot yet recruiting
- Hopital D Instruction Des Armées PercyClamart, FranceNot yet recruiting
- University Hospital Of Clermont-FerrandClermont-Ferrand, FranceNot yet recruiting
- Centre Hospitalier Sud FrancilienCorbeil Essonnes Cedex, FranceNot yet recruiting
- Assistance Publique Hopitaux De ParisCreteil Cedex, FranceNot yet recruiting
- Centre Hospitalier Universitaire de DijonDijon, FranceNot yet recruiting
- L’Hopital Alexandra LepeveDunkirk Cedex 1, FranceNot yet recruiting
- Centre Hospitalier Annecy GenevoisEpagny Metz-tessy, FranceNot yet recruiting
- Centre Hospitalier Universitaire Grenoble AlpesGrenoble Cedex 9, FranceNot yet recruiting
- Centre Hospitalier De VersaillesLe Chesnay Rocquencourt, FranceNot yet recruiting
- Chorale Du Centre Hospitalier De LensLens, FranceNot yet recruiting
- Hopital Saint Vincent de PaulLille, FranceNot yet recruiting
- Centre Hospitalier Universitaire De LilleLille Cedex, FranceNot yet recruiting
- Centre Hospitalier Et Universitaire De LimogesLimoges Cedex 1, FranceNot yet recruiting
- Centre Leon BerardLyon, FranceNot yet recruiting
- Centre Hospitalier Regional De MarseilleMarseille, FranceNot yet recruiting
- Institut Paoli-CalmettesMarseille, FranceNot yet recruiting
- Grand Hopital de l'Est FrancilienMeaux, FranceNot yet recruiting
- Centre Hospital Region Metz ThionvilleMetz Cedex 03, FranceNot yet recruiting
- Centre Hospitalier Universitaire De MontpellierMontpellier Cedex 5, FranceNot yet recruiting
- Groupe Hospitalier de la Région de Mulhouse et Sud AlsaceMulhouse, FranceNot yet recruiting
- Hospital Hotel DieuNantes, FranceNot yet recruiting
- Centre Hospitalier Universitaire de NiceNice, FranceNot yet recruiting
- Centre Hospitalier Universitaire De NimesNimes Cedex 9, FranceNot yet recruiting
- Centre Hospitalier Universitaire D OrleansOrleans Cedex 2, FranceNot yet recruiting
- Assistance Publique Hopitaux de ParisParis, FranceNot yet recruiting
- Institut CurieParis, FranceNot yet recruiting
- Centre Hospitalier De PerpignanPerpignan Cedex, FranceNot yet recruiting
- Centre Hospitalier Universitaire de BordeauxPessac, FranceNot yet recruiting
- Hospices Civils de LyonPierre-Bénite, FranceNot yet recruiting
- Centre Hospitalier Universitaire de PoitiersPoitiers, FranceNot yet recruiting
- Hôpital NOVOPontoise, FranceNot yet recruiting
- Centre Hospitalier Universitaire ReimsReims Cedex, FranceNot yet recruiting
- Centre Hospitalier Universitaire de RennesRennes, FranceNot yet recruiting
- Centre hospitalier de RoubaixRoubaix, FranceNot yet recruiting
- Centre Henri BecquerelRouen Cedex, FranceNot yet recruiting
- Centre Hospitalier Universitaire de Saint EtienneSaint-Priest-en-Jarez, FranceNot yet recruiting
- Les Hopitaux Universitaires De StrasbourgStrasbourg Cedex 2, FranceNot yet recruiting
- Centre Hospitalier Universitaire de ToulouseToulouse, FranceNot yet recruiting
- Centre Hospitalier Régional Universitaire de ToursTours, FranceNot yet recruiting
- CHRU De NancyVandoeuvre Les Nancy, FranceNot yet recruiting
- Institut Gustave RoussyVillejuif, FranceNot yet recruiting
About the trial
What the trial wants to find out
Primary Objectives: Sub-study 1 (FLT3-ITD+ without CBF, comparative): To determine whether the addition of quizartinib to induction chemotherapy (7+3) results in a significant improvement in MRD response after one cycle, as assessed by PCR-NGS, compared to midostaurin added to 7+3 in patients 18-60 years of age with newly diagnosed FLT3-ITD AML without CBF AML.
Read full original descriptionShow less
Sub-study 2 (FLT3-ITD- salvage, comparative): To determine whether the addition of venetoclax to high-dose cytarabine (HDAC) results in a significant improvement in MRD response after one cycle, as assessed by multiparameter flow cytometry, compared to HDAC alone in patients 18 60 years of age with newly diagnosed FLT3 ITD negative AML (including CBF AML patients with FLT3 ITD) and with a suboptimal response to 7+3 induction (i.e., no response or CR/CRh/CRi with positive MFC MRD after one cycle of 7+3 induction).
Sub-study 3 (FLT3-ITD- responders, exploratory): To describe the effect of an MRD-guided program on overall survival (OS) in patients 18-60 years of age with newly diagnosed FLT3 ITD negative AML (including CBF AML patients with FLT3 ITD) and who achieved CR/CRh/CRi without MFC MRD after one cycle of 7+3 induction.
Main secondary objective: Sub-study 1 (FLT3-ITD+ without CBF, comparative): To determine whether the addition of Quizartinib to induction chemotherapy (7+3) and to consolidation chemotherapy (IDAC) results in a significant improvement in MRD response after two cycles (combined induction and consolidation), as assessed by FLT3 ITD PCR NGS, compared to the addition of Midostaurin in patients 18 60 years of age with newly diagnosed FLT3 ITD AML without CBF AML.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- Prospective evaluation of response to treatment by analysis of measurable residual disease in younger adult patients (18-60 years) with acute myeloid leukemia (AML). The Backbone InterGroup (BIG)-2 umbrella trial from the Acute Leukemia French Intergroup (ALFA, FILO) - BIG-2
- Plain-language title
- Treatment guided by leftover leukemia cells in adults with acute myeloid leukemiaGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Fit questions
- Built from 2026-525759-96-00, who can take part
- Record updated
- 23 October 2026